Nelitolimod (SD-101) via PEDD™ + systemic checkpoint inhibitors
Hepatocellular Carcinoma (HCC)
Key Facts
About TriSalus Life Sciences
TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.
View full company profileAbout TriSalus Life Sciences
TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.
View full company profileAbout TriSalus Life Sciences
TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.
View full company profileAbout TriSalus Life Sciences
TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.
View full company profileAbout TriSalus Life Sciences
TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 2/3 |
| Fostroxacitabine bralpamide (MIV-818) | Medivir | Phase 2a |
| YntraDose | BetaGlue Therapeutics | Pre-clinical |
| seRNA 001 | SRTD biotech | Preclinical |
| Seravue® (Diagnostic Assay) | ImCare Biotech | Development |
| BC3402 + IMFINZI | BioCity Biopharma | Phase 1b/2 |
| ZW251 | Zymeworks | Phase 1 |
| TTI-101 | Tvardi Therapeutics | Phase 1b/2 |